Breathe eCig Corp. Appoints Veteran Pharmaceutical Industry Executive Frank P. Orlowski as Advisory Board Member
NEW YORK, Apr. 21, 2015 /PRNewswire/ -- Breathe eCig Corp. (OTCQB: BVAP) ("Breathe" or "the Company"), the electronic cigarette industry innovator and pioneer, has today announced the appointment of Frank P. Orlowski ("Mr. Orlowski") as the first member of the Company's Advisory Board. Currently, Mr. Orlowski holds the positions of senior director finance, emerging markets and transition manufacturing sites at Pfizer, Inc. ("Pfizer"), one of the world's largest pharmaceutical companies. In his capacity on the Advisory Board, Mr. Orlowski will leverage his extensive industry experience to assist Breathe in effectively developing intellectual property, establishing joint venture partnerships and efficiently targeting market segments.
Breathe CEO Mr. Josh Kimmel stated, "The Company is thrilled to have the opportunity to work with Mr. Orlowski and learn from his many years of experience in the pharmaceutical sector, as well as manufacturing. He shares our enthusiasm about the future of Breathe's products and technology as we strive to build the best and most socially responsible product in a large and fast growing industry. We are already having discussions about some innovative ideas with respect to marketing, joint ventures and patent applications."
Upon his Advisory Board appointment, Mr. Frank Orlowski expressed, "I am excited to assist the talented team of entrepreneurs at Breathe eCig Corp. identify potentially important market opportunities. I am impressed with Breathe's socially responsible approach at building its products and devices and look forward to providing my expertise as the company penetrates a large and rapidly changing market."
FRANK P. ORLOWSKI, Age 44 -- PERSONAL BIO BELOW:
Pfizer Inc., New York, NY: 1996-Present
Frank Orlowski has over 20 years' experience in the pharmaceutical industry in positions of increased responsibility in strategy, finance and operations. Prior to Pfizer, he worked at Accenture on various successful strategic consulting engagements in manufacturing. Frank was responsible for the global integration of Warner Lambert and Pharmacia into Pfizer and was Project Lead for the global rollout of several widely used information systems.
Frank is currently responsible for managing all aspects of Emerging Markets Manufacturing Supply Finance. In this global role he develops operational strategies for internal and external pharmaceutical supply chain and sourcing throughout Asia, Africa/Middle East and South America. As a global Pfizer leader he is highly effective working in a multi-cultural, global organization partnering with senior government officials and business leaders, both inside and outside Pfizer and the pharmaceutical industry. He manages a large team across the globe and is responsible for a yearly operating budget of over $900 million. The specific countries which he supports from a Pfizer manufacturing and business development standpoint include Argentina, Brazil, China (all provinces), Egypt, India, Indonesia, Japan, Korea, Mexico, Morocco, Russia, Singapore, Turkey, Tunisia, Thailand and Venezuela.
Frank currently sits on the leadership team of several innovating manufacturing and drug development teams within Pfizer alongside senior Pfizer scientists. This includes evaluating external business development and licensing opportunities.
Frank was recently appointed to the board of the American Cancer Society and serves on the Executive Board of the National Corporate Theatre Fund. Frank earned a BS in accounting from Providence College and an MBA from NYU Stern School of Business. He completed two New York City Marathons and over 20 half marathons.
About BREATHE ECIG CORP. (OTCQB: BVAP):
Breathe was founded in 2012 as a research and development company in Knoxville, Tennessee with the mission to develop a better e-cigarette than was available on the market. Now holding multiple patents (pending) for its groundbreaking product, BVAP, Breathe is not your typical e-cig manufacturer. With a commitment to remaining socially responsible through innovative product development, consumer outreach and education, Breathe challenges the e-cig industry establishment. To find out more, visit www.breathecig.com.
DISCLAIMER < >
This press release contains statements that are "Forward-Looking" in nature (within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). All statements regarding the Company's financial position, potential, business strategy, plans and objectives for future operations are Forward-Looking statements. Many of these statements contain words such as "goal," "aims," "may," "expect," "believe," "intend," "anticipate," "estimate," "continue," "would," "exceed," "should," "steady," "plan," "potential," "dramatic," and variations of such words and similar expressions identify Forward-Looking statements, but their absence does not mean that a statement is not a Forward-Looking statement. Because Forward-Looking statements involve future risks and uncertainties, there are many factors that could cause actual results to differ materially from those expressed or implied. The Company cannot predict the actual effect these factors will have on its results and many of the factors and their effects are beyond the Company's control. Any forward-looking statement made by the Company speaks only as of the date on which it is made. The Company is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, subsequent events or otherwise. Given these uncertainties, you should not rely too heavily on these forward-looking statements.
Pfizer, Inc. is not an investor in Breathe eCig Corp. and the two companies do not presently have any type of business relationship.
Information for the Educated Investor
For further information regarding these and other risks related to Breathe eCigs' business, investors should consult Breathe eCigs' filings with the Securities and Exchange Commission, available at www.sec.gov, and contact Company counsel at [email protected].
Contact:
Mr. Joshua Kimmel
Chief Executive Officer
Tel: +1-800-905-4014
Local: +1-865-337-7549
[email protected]
MEDIA CONTACT:
Heather Ripley
Ripley PR
+1-865-977-1973
[email protected]
SOURCE Breathe eCig Corp.
Share this article